Quetiapine Fumarate Extended-Release Tablets Recalled for Incorrect Package Insert
The Harvard Drug Group is recalling Quetiapine Fumarate Extended-Release Tablets because they were packaged with the wrong package insert.
What this means for you
Cosmetic or documentation issue. No expected health impact, but the manufacturer is correcting the affected products.
Our severity reasoning: The recall is classified as FDA Class III, which the rubric defines as typically resulting in a score of 1 or 2 because it is unlikely to cause adverse health consequences. The issue is a packaging/labeling error.
Plain-English summary
The Harvard Drug Group is recalling Quetiapine Fumarate Extended-Release Tablets, 300 mg, 100 tablets per unit dose carton. The recall is due to a labeling error where the product was packaged with the package insert for Quetiapine Fumarate Tablets instead of the correct insert for the Extended-Release Tablets.
The affected product is manufactured by Lupin Limited in India and distributed by Major Pharmaceuticals in Livonia, Michigan. The specific lot number is N00037 with an expiration date of 05/2021. The product was distributed nationwide.
Consumers and healthcare providers should stop using the affected product and contact their pharmacist or healthcare provider for a replacement or refund. This recall is classified as Class III by the FDA, indicating that use of or exposure to the product is not likely to cause adverse health consequences.
The recalled product
- Product
- QUETIAPINE (QUETIAPINE)
- Brand
- QUETIAPINE
- Manufacturer
- The Harvard Drug Group
- Category
- Drug — Prescription Drug
- Hazard
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (3)
- Lot
- expiry: Lot N00037
- exp 05/2021
Distribution
Distributed nationwide across the United States.
Part of a larger recall action
This product is one of 4 recalled by The Harvard Drug Group under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 4 products in this recall →Related recalls
Same brand · QUETIAPINE
- LowQuetiapine Fumarate Extended-Release Tablets Recalled for Incorrect Package Insert
FDA (Drugs) · 2020-03-18
- LowQuetiapine Fumarate Extended-Release Tablets Recalled for Incorrect Package Insert
FDA (Drugs) · 2020-03-18
- LowQuetiapine Fumarate Extended-Release Tablets Recalled for Incorrect Package Insert
FDA (Drugs) · 2020-03-18
- HighAscend Recalls Quetiapine Tablets Due to Metal Shard Contamination
FDA (Drugs) · 2018-12-05
Same manufacturer · The Harvard Drug Group
See all →- ModerateTramadol Hydrochloride Tablets Recalled Due to Inadequate Blister Packaging Seal
FDA (Drugs) · 2023-07-05
- ModerateGabapentin tablets recalled due to product mixup with foreign tablet
FDA (Drugs) · 2023-05-17
- HighCarbidopa and Levodopa Tablets Recalled for Inadequate Blister Packaging Seal
FDA (Drugs) · 2023-03-08
- ModeratehydrALAZINE HCl Tablets 10 mg Recalled for Failed Impurity Specifications
FDA (Drugs) · 2022-03-23
- ModeratePaliperidone Extended-Release Tablets Recalled for Failed Dissolution
FDA (Drugs) · 2022-03-16
Same hazard · mis labeling
See all →- ModerateMedline Trach Tube Kit Recalled for Component Labeling Discrepancy
FDA (Devices) · 2026-09-02
- ModerateAVID Medical Recalls Halyard Total Joint Kits for Latex Labeling Deficiency
FDA (Devices) · 2026-09-02
- ModerateOlympus Recalls PowerSeal Sealer Due to Incorrect Outer Box Labeling
FDA (Devices) · 2026-09-02
- HighSura Tanmen Ramen Noodles Recalled for Undeclared Fish Allergens
FDA (Food) · 2026-09-02
- SevereWhite Vein Advanced Alkaloids Chewable Tablets Recall for Excess Active Ingredient
FDA (Food) · 2026-09-02